I’m feeling equivocal about this. @Outlander2 might be the best person to shed in-depth light.
primary endpoint of reduced iron in substantia niagra was not statistically significant (SS) and so were the nfl values which were not SS.
As long as the UMSARS is a well validated and reproducible tool, we are fine there.
I couldn’t see any SS on the other markers they analyzed like NNIPS motor score as well as motor symptom duration.
the wearable sensor showed mixed improvement with the 50/75mg dosing. And they rightly said it needs to be analyzed and perhaps is based on the heterogeneity of the disease.
we need to bear in mind it’s a small sample size given the rarity of the disease.
my 2 cents, we will be definitely pushed into a phase 3 with a bigger sample size to really ratify findings.
- Forums
- ASX - By Stock
- Ann: Alterity Phase 2 Presentation at AAN 2025
ATH
alterity therapeutics limited
Add to My Watchlist
0.00%
!
1.1¢

I’m feeling equivocal about this. @Outlander2 might be the best...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $100.4M |
Open | High | Low | Value | Volume |
1.0¢ | 1.1¢ | 1.0¢ | $60.81K | 5.737M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
37 | 16255465 | 1.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.1¢ | 1643984 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
32 | 9305965 | 0.010 |
30 | 26756594 | 0.009 |
15 | 25470226 | 0.008 |
12 | 23772392 | 0.007 |
15 | 24953518 | 0.006 |
Price($) | Vol. | No. |
---|---|---|
0.011 | 1643984 | 2 |
0.012 | 20418298 | 32 |
0.013 | 7744325 | 14 |
0.014 | 13188180 | 7 |
0.015 | 2059976 | 9 |
Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |